Dose-Related Effects of Adjunctive Ketamine in Taiwanese Patients with Treatment-Resistant Depression

The antidepressant effects of ketamine are thought to depend on brain-derived neurotrophic factor (BDNF) genotype and dose. The purpose of this study was to characterize the dose-related antidepressant effects of ketamine in patients with treatment-resistant depression drawn from a Chinese population predominately possessing lower activity BDNF genotypes (Val/Met, Met/Met). We conducted a double-blind, randomized, parallel-group, placebo-controlled trial of a single ketamine infusion (saline, 0.2 mg/kg, 0.5 mg/kg). Patients (N=71; BDNF genotype: Val/Val (N=12, 17%), Val/Met (N=40, 56.3%), and Met/Met (N=19, 26.8%)) received mood ratings before infusion, after infusion, and for the subsequent 14 days. Plasma ketamine levels and BDNF genotypes were assessed. This study found a significant dose-related ketamine effect on scores on the Hamilton Depression Rating Scale (HAMD). The responder analysis (>50% reduction from baseline HAMD on at least 2 days between days 2 and 5) also revealed a significant dose-related effect (saline: 12.5%, 0.2 mg/kg: 39.1%; 0.5 mg/kg: 45.8%). This is the first report to our knowledge to demonstrate the dose-related efficacy of R/S-ketamine for treatment-resistant depression and the first to characterize ketamine effects in a genotyped Chinese population in which most (83%) patients possessed at least one copy of the lower functioning Met allele of the BDNF gene.

[1]  Se-Won Lim,et al.  Brain-derived neurotrophic factor gene polymorphism (Val66Met) and citalopram response in major depressive disorder , 2006, Brain Research.

[2]  Husseini Manji,et al.  Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study , 2016, Biological Psychiatry.

[3]  D. Luckenbaugh,et al.  Simultaneous population pharmacokinetic modelling of ketamine and three major metabolites in patients with treatment-resistant bipolar depression. , 2012, British journal of clinical pharmacology.

[4]  G. Laje,et al.  Relationship of Ketamine's Plasma Metabolites with Response, Diagnosis, and Side Effects in Major Depression , 2012, Biological Psychiatry.

[5]  M. Fava,et al.  What Did STAR✫D Teach Us? Results From a Large-Scale, Practical, Clinical Trial for Patients With Depression , 2012 .

[6]  John H Krystal,et al.  Antidepressant effects of ketamine in depressed patients , 2000, Biological Psychiatry.

[7]  Bang-Hung Yang,et al.  The effects of low‐dose ketamine on the prefrontal cortex and amygdala in treatment‐resistant depression: A randomized controlled study , 2016, Human brain mapping.

[8]  K. Hashimoto,et al.  Association between brain‐derived neurotrophic factor 196 G/A polymorphism and personality traits in healthy subjects , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[9]  F. McMahon,et al.  Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Antidepressant Efficacy of Ketamine in Depressed Patients , 2012, Biological Psychiatry.

[10]  J. Krystal,et al.  Rapid-Acting Glutamatergic Antidepressants: The Path to Ketamine and Beyond , 2013, Biological Psychiatry.

[11]  I. Feinberg,et al.  Stimulation of NREM Delta EEG by Ketamine Administration during Waking: Demonstration of Dose Dependence , 1995, Neuropsychopharmacology.

[12]  Kangguang Lin,et al.  Brain-derived neurotrophic factor gene polymorphism (Val66Met) and the early response to antidepressant in Chinese Han population. , 2012, Psychiatric genetics.

[13]  M. Hamilton.  A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[14]  C. Correll,et al.  Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study , 2015, Psychological Medicine.

[15]  D. Kupfer,et al.  Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. , 2004, Controlled clinical trials.

[16]  Harlan M. Krumholz,et al.  Reevaluating the Efficacy and Predictability of Antidepressant Treatments: A Symptom Clustering Approach , 2017, JAMA psychiatry.

[17]  A. Maurset,et al.  Interaction of the chiral forms of ketamine with opioid, phencyclidine, σ and muscarinic receptors , 1995 .

[18]  Nick Glozier,et al.  Effects of Low-Dose and Very Low-Dose Ketamine among Patients with Major Depression: a Systematic Review and Meta-Analysis , 2015, The international journal of neuropsychopharmacology.

[19]  Blair T. Johnson,et al.  Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration , 2008, PLoS medicine.

[20]  A. Belger,et al.  Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. , 2005, Archives of general psychiatry.

[21]  Xi-Ping Huang,et al.  NMDAR inhibition-independent antidepressant actions of ketamine metabolites , 2016, Nature.

[22]  I. Oye,et al.  Interaction of the chiral forms of ketamine with opioid, phencyclidine, sigma and muscarinic receptors. , 1995, Pharmacology & toxicology.

[23]  Paresh D Patel,et al.  Variant Brain-Derived Neurotrophic Factor (BDNF) (Met66) Alters the Intracellular Trafficking and Activity-Dependent Secretion of Wild-Type BDNF in Neurosecretory Cells and Cortical Neurons , 2004, The Journal of Neuroscience.

[24]  D. Revicki,et al.  Telephone assessment of depression severity. , 1993, Journal of psychiatric research.

[25]  E. Ballard,et al.  Antisuicidal Response Following Ketamine Infusion Is Associated With Decreased Nighttime Wakefulness in Major Depressive Disorder and Bipolar Disorder. , 2017, The Journal of clinical psychiatry.

[26]  J. Overall,et al.  The Brief Psychiatric Rating Scale , 1962 .

[27]  K. Hagi,et al.  Single-dose infusion ketamine and non-ketamine N-methyl-d-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories , 2016, Psychological Medicine.

[28]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[29]  Dennis S. Charney,et al.  Ketamine for Depression: Where Do We Go from Here? , 2012, Biological Psychiatry.

[30]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[31]  G. Aghajanian,et al.  Brain-Derived Neurotrophic Factor Val66Met Allele Impairs Basal and Ketamine-Stimulated Synaptogenesis in Prefrontal Cortex , 2012, Biological Psychiatry.

[32]  D. Luckenbaugh,et al.  An assessment of the anti-fatigue effects of ketamine from a double-blind, placebo-controlled, crossover study in bipolar disorder. , 2016, Journal of affective disorders.

[33]  I. Feinberg,et al.  Ketamine Administration During Waking Increases Delta EEG Intensity in Rat Sleep , 1993, Neuropsychopharmacology.

[34]  D. Luckenbaugh,et al.  Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. , 2017, Journal of affective disorders.